ANI Pharmaceuticals (ANIP) EBITDA margin US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | 1.44% | 7.91% | 21.9% | 10.3% | 23.5% | 25.7% | ||
| Changes by years, y/y, % | -12pp | +6pp | +14pp | -12pp | +13pp | +11.7% | |||
ANI Pharmaceuticals. EBITDA margin, %
ANI Pharmaceuticals. EBITDA margin, changes, pp
ANI Pharmaceuticals (ANIP) EBITDA margin US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EBITDA margin, % | ? | 24.5% | 18.6% | 26.8% | 31.1% | 25.1% | 25.7% | |
| Changes by years, y/y, % | -8pp | +6pp | +36pp | +23pp | +1pp | |||
| Changes by quarters, q/q, % | +17pp | -6pp | +8pp | +4pp | -6pp | |||